The head and neck cancer therapeutics market size has grown rapidly in recent years. It will grow from $1.55 billion in 2023 to $1.73 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth observed in previous periods can be attributed to increased sales in the tobacco and alcohol industries, rising cases of human papillomavirus (HPV) infections, environmental exposures, and advancements in treatment methods.
The head and neck cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The projected growth can be credited to advancements in immunotherapy, the adoption of precision medicine strategies, increased awareness through early diagnosis initiatives, and the expanding aging population worldwide. Key trends in the forecast period encompass the growing utilization of targeted therapies, the integration of minimally invasive surgical methods, the incorporation of palliative care, exploration into new biomarkers, and the implementation of patient-centric care models.
The rising prevalence of head and neck cancer is anticipated to drive the growth of the head and neck cancer therapeutics market. This medical condition involves the uncontrolled growth of cells in the tissues of the head and neck region, necessitating improved diagnostic and treatment options to address mutations and abnormalities in cancer cells. In 2023, projections from Cancer Research UK indicate a 3% increase in the incidence of head and neck cancer in the UK between 2023 and 2025. Additionally, deaths attributed to head and neck cancers are expected to rise by 12% during the same period, underscoring the growing need for effective therapeutic interventions.
The consumption of tobacco and alcohol at high levels is expected to contribute to the expansion of the head and neck cancer therapeutics market. Habitual use of tobacco products and alcoholic beverages exposes the lining of the mouth, throat, larynx, and other areas to carcinogenic substances, leading to an increased risk of head and neck cancer. Notably, in August 2023, the American Academy of Family Physicians reported a significant surge in e-cigarette unit sales, rising by over 46% from January 2020 to December 2022. This increase, along with a rise in e-cigarette use among U.S. adults to 6% in 2022 from 3.7% in 2020, emphasizes the impact of high tobacco consumption on the prevalence of head and neck cancer, thereby driving the demand for therapeutic solutions.
Leading companies in the head and neck cancer therapeutics market are focused on introducing novel drug treatments to address the needs of patients with head and neck cancer. Drug treatment involves the use of pharmaceutical substances to manage or alleviate medical conditions, and in October 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, achieved FDA approval for its latest drug, 'Loqtorzi' (toripalimab-tpzi). The approval allows for the use of the drug in combination with cisplatin and gemcitabine as the initial treatment for adults diagnosed with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The clinical trial demonstrated favorable results, with adverse reactions occurring in fewer than 20% of patients, whether used as a first-line option or as a single-agent therapy.
Major players in the head and neck cancer therapeutics market are also dedicated to developing innovative solutions, such as AI-enabled MR (Magnetic Resonance) imaging. This approach involves incorporating artificial intelligence (AI) technology into the MR process, optimizing various aspects from image acquisition to interpretation. In October 2022, Koninklijke Philips N.V., a Netherlands-based health technology company, received FDA approval for two advances in MR-only workflows such as (AI)-enabled MRCAT Head and Neck' and 'MacroMedics.' The (AI)-enabled MRCAT Head and Neck radiotherapy application facilitates the use of MR as the exclusive or primary imaging modality for planning radiotherapy, especially for soft tissue tumors located in the head and neck, as well as in the brain, pelvis, and prostate.
In March 2023, InvoX Pharma Ltd., a UK-based biopharmaceutical company, completed the acquisition of F-star Therapeutics Inc. for a sum of $161 million. This strategic move fortified InvoX Pharma's standing in the cancer therapeutics sector, expanding its portfolio and broadening its market reach. F-star Therapeutics Inc., based in the US, specializes in clinical-stage biopharmaceuticals, particularly focusing on head and neck cancer immunotherapy.
Major companies operating in the head and neck cancer therapeutics market report are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.
North America was the largest region in the head and neck cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary types of head and neck cancer therapeutics are programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. PD inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, function by obstructing interactions between PD-1 and its ligands, PD-L1 and PD-L2, present in certain cancer cells. These medications are administered through injectable or oral routes and are available through multiple distribution channels such as retail and specialty pharmacies, hospital pharmacies, and online pharmacies. They find application in surgery, radiation therapy, chemotherapy, immunotherapy, and other treatment modalities.
The head and neck cancer therapeutics research report is one of a series of new reports that provides head and neck cancer therapeutics market statistics, including the head and neck cancer therapeutics industry's global market size, regional shares, competitors with head and neck cancer therapeutics market share, detailed head and neck cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer therapeutics industry. This head and neck cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The head and neck cancer therapeutics market consists of sales of bleomycin sulfate, cetuximab, docetaxel, and erbitux. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The head and neck cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The projected growth can be credited to advancements in immunotherapy, the adoption of precision medicine strategies, increased awareness through early diagnosis initiatives, and the expanding aging population worldwide. Key trends in the forecast period encompass the growing utilization of targeted therapies, the integration of minimally invasive surgical methods, the incorporation of palliative care, exploration into new biomarkers, and the implementation of patient-centric care models.
The rising prevalence of head and neck cancer is anticipated to drive the growth of the head and neck cancer therapeutics market. This medical condition involves the uncontrolled growth of cells in the tissues of the head and neck region, necessitating improved diagnostic and treatment options to address mutations and abnormalities in cancer cells. In 2023, projections from Cancer Research UK indicate a 3% increase in the incidence of head and neck cancer in the UK between 2023 and 2025. Additionally, deaths attributed to head and neck cancers are expected to rise by 12% during the same period, underscoring the growing need for effective therapeutic interventions.
The consumption of tobacco and alcohol at high levels is expected to contribute to the expansion of the head and neck cancer therapeutics market. Habitual use of tobacco products and alcoholic beverages exposes the lining of the mouth, throat, larynx, and other areas to carcinogenic substances, leading to an increased risk of head and neck cancer. Notably, in August 2023, the American Academy of Family Physicians reported a significant surge in e-cigarette unit sales, rising by over 46% from January 2020 to December 2022. This increase, along with a rise in e-cigarette use among U.S. adults to 6% in 2022 from 3.7% in 2020, emphasizes the impact of high tobacco consumption on the prevalence of head and neck cancer, thereby driving the demand for therapeutic solutions.
Leading companies in the head and neck cancer therapeutics market are focused on introducing novel drug treatments to address the needs of patients with head and neck cancer. Drug treatment involves the use of pharmaceutical substances to manage or alleviate medical conditions, and in October 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, achieved FDA approval for its latest drug, 'Loqtorzi' (toripalimab-tpzi). The approval allows for the use of the drug in combination with cisplatin and gemcitabine as the initial treatment for adults diagnosed with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The clinical trial demonstrated favorable results, with adverse reactions occurring in fewer than 20% of patients, whether used as a first-line option or as a single-agent therapy.
Major players in the head and neck cancer therapeutics market are also dedicated to developing innovative solutions, such as AI-enabled MR (Magnetic Resonance) imaging. This approach involves incorporating artificial intelligence (AI) technology into the MR process, optimizing various aspects from image acquisition to interpretation. In October 2022, Koninklijke Philips N.V., a Netherlands-based health technology company, received FDA approval for two advances in MR-only workflows such as (AI)-enabled MRCAT Head and Neck' and 'MacroMedics.' The (AI)-enabled MRCAT Head and Neck radiotherapy application facilitates the use of MR as the exclusive or primary imaging modality for planning radiotherapy, especially for soft tissue tumors located in the head and neck, as well as in the brain, pelvis, and prostate.
In March 2023, InvoX Pharma Ltd., a UK-based biopharmaceutical company, completed the acquisition of F-star Therapeutics Inc. for a sum of $161 million. This strategic move fortified InvoX Pharma's standing in the cancer therapeutics sector, expanding its portfolio and broadening its market reach. F-star Therapeutics Inc., based in the US, specializes in clinical-stage biopharmaceuticals, particularly focusing on head and neck cancer immunotherapy.
Major companies operating in the head and neck cancer therapeutics market report are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.
North America was the largest region in the head and neck cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary types of head and neck cancer therapeutics are programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. PD inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, function by obstructing interactions between PD-1 and its ligands, PD-L1 and PD-L2, present in certain cancer cells. These medications are administered through injectable or oral routes and are available through multiple distribution channels such as retail and specialty pharmacies, hospital pharmacies, and online pharmacies. They find application in surgery, radiation therapy, chemotherapy, immunotherapy, and other treatment modalities.
The head and neck cancer therapeutics research report is one of a series of new reports that provides head and neck cancer therapeutics market statistics, including the head and neck cancer therapeutics industry's global market size, regional shares, competitors with head and neck cancer therapeutics market share, detailed head and neck cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer therapeutics industry. This head and neck cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The head and neck cancer therapeutics market consists of sales of bleomycin sulfate, cetuximab, docetaxel, and erbitux. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Head and Neck Cancer Therapeutics Market Characteristics3. Head and Neck Cancer Therapeutics Market Trends and Strategies32. Global Head and Neck Cancer Therapeutics Market Competitive Benchmarking33. Global Head and Neck Cancer Therapeutics Market Competitive Dashboard34. Key Mergers and Acquisitions in the Head and Neck Cancer Therapeutics Market
4. Head and Neck Cancer Therapeutics Market - Macro Economic Scenario
5. Global Head and Neck Cancer Therapeutics Market Size and Growth
6. Head and Neck Cancer Therapeutics Market Segmentation
7. Head and Neck Cancer Therapeutics Market Regional and Country Analysis
8. Asia-Pacific Head and Neck Cancer Therapeutics Market
9. China Head and Neck Cancer Therapeutics Market
10. India Head and Neck Cancer Therapeutics Market
11. Japan Head and Neck Cancer Therapeutics Market
12. Australia Head and Neck Cancer Therapeutics Market
13. Indonesia Head and Neck Cancer Therapeutics Market
14. South Korea Head and Neck Cancer Therapeutics Market
15. Western Europe Head and Neck Cancer Therapeutics Market
16. UK Head and Neck Cancer Therapeutics Market
17. Germany Head and Neck Cancer Therapeutics Market
18. France Head and Neck Cancer Therapeutics Market
19. Italy Head and Neck Cancer Therapeutics Market
20. Spain Head and Neck Cancer Therapeutics Market
21. Eastern Europe Head and Neck Cancer Therapeutics Market
22. Russia Head and Neck Cancer Therapeutics Market
23. North America Head and Neck Cancer Therapeutics Market
24. USA Head and Neck Cancer Therapeutics Market
25. Canada Head and Neck Cancer Therapeutics Market
26. South America Head and Neck Cancer Therapeutics Market
27. Brazil Head and Neck Cancer Therapeutics Market
28. Middle East Head and Neck Cancer Therapeutics Market
29. Africa Head and Neck Cancer Therapeutics Market
30. Head and Neck Cancer Therapeutics Market Competitive Landscape and Company Profiles
31. Head and Neck Cancer Therapeutics Market Other Major and Innovative Companies
35. Head and Neck Cancer Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Head and Neck Cancer Therapeutics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on head and neck cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for head and neck cancer therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Programmed Cell Death (PD) Inhibitors; Microtubule Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) By Route Of Administration: Injectable; Oral
3) By Distribution Channel: Retail and Specialty Pharmacies; Hospital Pharmacies; Online Pharmacies
4) By Application: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Other Applications
Key Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- F Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi Aventis LLC
- Bristol-Myers-Squibb Company
- AstraZeneca PLC
- GlaxoSmithKline plc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Incyte Corporation
- Ono Pharmaceutical Co. Ltd.
- Kyowa Kirin Co. Ltd.
- Hikma Pharmaceuticals PLC
- Clinigen Group plc.
- Ligand Pharmaceuticals
- Acceleron Pharma Inc.
- Taiho Pharmaceutical Co. Ltd.
- Boston Biomedical Inc.
- AB Science SA.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 1.73 Billion |
| Forecasted Market Value ( USD | $ 2.57 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
